JZT(SZ:000989)2021-08-13 16:00Financial Performance - The company's operating revenue for the first half of 2021 was ¥2,078,317,243.58, representing a 13.39% increase compared to ¥1,832,973,643.40 in the same period last year[27]. - The net profit attributable to shareholders of the listed company was ¥219,555,404.03, an increase of 11.38% from ¥197,114,952.81 in the previous year[27]. - The net profit after deducting non-recurring gains and losses was ¥194,490,937.16, showing a slight increase of 1.42% compared to ¥191,775,585.27 in the same period last year[27]. - The net cash flow from operating activities decreased by 17.53% to ¥249,323,477.96 from ¥302,317,055.73 in the previous year[27]. - The total assets at the end of the reporting period were ¥5,254,966,396.63, reflecting a 3.62% increase from ¥5,071,508,340.80 at the end of the previous year[27]. - The net assets attributable to shareholders of the listed company decreased by 0.64% to ¥3,897,302,533.87 from ¥3,922,517,553.92 at the end of the previous year[27]. - The basic earnings per share increased by 9.63% to ¥0.2573 from ¥0.2347 in the same period last year[27]. - The diluted earnings per share also increased by 9.63% to ¥0.2573 from ¥0.2347 in the previous year[27]. - The weighted average return on net assets was 5.43%, up from 4.89% in the previous year, an increase of 0.54%[27]. Revenue and Growth - The company achieved a revenue of 2,078.32 million CNY, representing a year-on-year growth of 13.39%[51]. - The pharmaceutical industry segment generated ¥1,556,272,739.77 in revenue, accounting for 74.88% of total operating revenue, with a year-on-year growth of 14.82%[84]. - The Northeast region saw a significant revenue increase of 48.92%, reaching ¥291,379,925.53, driven by efforts to develop untapped markets[87]. Research and Development - The company holds 309 national drug registration approvals, including 35 exclusive varieties and 1 protected traditional Chinese medicine variety[41]. - The clinical trial for the stem cell project targeting ischemic stroke officially commenced, with the first subject successfully dosed without adverse reactions[58]. - The LFG project received FDA approval for clinical trials in the U.S., marking a significant milestone in the development of a new anticoagulant drug[59]. - The YB211 project, an innovative cyclic peptide antibiotic, made progress in preclinical research, including process optimization and quality standard establishment[60]. - The REMD-477 project demonstrated significant clinical results in a Phase II trial for Type 1 diabetes, showing reductions in hemoglobin A1c and daily insulin usage[61]. - The company is actively conducting re-evaluation work for its Shuxuetong injection, which has been recognized for its clinical significance in preventing recurrent strokes[64]. - The Tianma Gouteng Granules project is progressing as part of a national key research plan, with a multi-center clinical trial involving 500 patients to evaluate its efficacy in treating hypertension[65]. - Ongoing research and development efforts are being made to enhance the clinical value of existing products, expanding their indications and improving their marketability[66]. - The company submitted 5 patent applications and received 4 patents, including 2 invention patents during the reporting period[67]. Strategic Initiatives - A strategic cooperation agreement was signed with JD Health to enhance online operations and develop health products, with a focus on e-commerce and digital marketing[67]. - The company launched its flagship stores on JD Health, primarily selling health-related products, and is developing unique product lines[67]. - A strategic cooperation agreement was established with Nanshan Holdings to explore R&D in traditional Chinese medicine and health products[68]. - The company is adapting its market strategies in response to policy changes and environmental shifts to strengthen its strategic product lines[51]. - The company is actively exploring new product development and modern sales models, including e-commerce and micro-commerce[49]. Environmental Compliance - The company reported a total nitrogen discharge of 9.02 mg/L, which is below the standard limit of 45 mg/L, with a total discharge amount of 0.4 tons[135]. - The company achieved a Chemical Oxygen Demand (COD) level of 86 mg/L, significantly below the regulatory limit of 500 mg/L, with a total discharge of 3.92 tons[135]. - The company maintained a Suspended Solids (SS) level of 21 mg/L, well within the permissible limit of 400 mg/L, with a total discharge of 0.95 tons[135]. - The company recorded an ammonia nitrogen level of 4.79 mg/L, which is below the limit of 45 mg/L, with a total discharge of 0.21 tons[135]. - The company reported a total phosphorus discharge of 1.48 mg/L, with a total discharge of 0.067 tons, and no exceedance of standards[135]. - The company’s BOD5 level was 46.6 mg/L, significantly below the limit of 300 mg/L, with a total discharge of 2.12 tons[135]. - The company has implemented effective measures to ensure that all reported emissions are within regulatory limits, with no exceedances reported[135]. - The company has established a comprehensive environmental monitoring platform to ensure compliance with environmental regulations and to fulfill social responsibilities[154]. - The company has been recognized as a provincial-level environmental integrity unit for the year 2020 in Hunan Province[154]. Shareholding Structure - The total number of shares before the recent change was 869,354,236, with 32.19% being restricted shares and 67.81% being unrestricted shares[196]. - The number of restricted shares decreased by 25,052,989, resulting in a total of 254,758,396 restricted shares, which now represent 29.30% of the total shares[196]. - The unrestricted shares increased by 25,052,989, bringing the total to 614,595,840, which accounts for 70.70% of the total shares[196]. - The largest shareholder, Li Zhenguo, had 275,987,140 restricted shares at the beginning, with 21,585,000 shares released, leaving 254,402,140 restricted shares[200]. - The total number of restricted shares released during this period was 21,585,000, affecting the overall shareholding structure[200]. - The company has a total of 276,343,396 restricted shares held by executives, with a release mechanism of 25% of their holdings each year[200]. - The company’s shareholding structure indicates a significant portion of shares held by domestic natural persons, totaling 279,811,385 before the change[196]. - The overall shareholding ratio of domestic and foreign investors remains stable, with no significant changes reported[196]. - The company continues to comply with regulatory requirements regarding shareholding disclosures and changes[199].